- Previous Close
10.46 - Open
10.40 - Bid 9.62 x 1000
- Ask 9.65 x 800
- Day's Range
9.43 - 10.54 - 52 Week Range
5.26 - 64.40 - Volume
1,135,845 - Avg. Volume
1,587,727 - Market Cap (intraday)
561.281M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
-- - EPS (TTM)
-12.89 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.40
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
www.ginkgobioworks.comRecent News: DNA
View MorePerformance Overview: DNA
Trailing total returns as of 2/25/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNA
View MoreValuation Measures
Market Cap
601.23M
Enterprise Value
430.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.45
Price/Book (mrq)
0.75
Enterprise Value/Revenue
1.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-298.78%
Return on Assets (ttm)
-19.19%
Return on Equity (ttm)
-63.51%
Revenue (ttm)
217.95M
Net Income Avi to Common (ttm)
-651.19M
Diluted EPS (ttm)
-12.89
Balance Sheet and Cash Flow
Total Cash (mrq)
616.21M
Total Debt/Equity (mrq)
55.84%
Levered Free Cash Flow (ttm)
-195.73M